The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 02, 2016
Filed:
Feb. 20, 2015
Applicant:
Mei Pharma, Inc., San Diego, CA (US);
Inventors:
DiZhong Chen, Singapore, SG;
Hong Yan Song, Singapore, SG;
Eric T. Sun, Singapore, SG;
Niefang Yu, Singapore, SG;
Yong Zou, Beijing, CN;
Assignee:
MEI PHARMA, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/444 (2006.01); A61K 31/506 (2006.01); C04B 35/632 (2006.01); C07D 235/06 (2006.01); C07D 235/08 (2006.01); C07D 235/14 (2006.01); C07D 235/18 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/02 (2006.01); C07D 409/04 (2006.01); C07D 413/02 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); C07D 403/06 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); C04B 35/632 (2013.01); C07D 235/06 (2013.01); C07D 235/08 (2013.01); C07D 235/14 (2013.01); C07D 235/18 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/02 (2013.01); C07D 403/06 (2013.01); C07D 409/04 (2013.01); C07D 413/02 (2013.01); G01N 33/5011 (2013.01); G01N 33/6875 (2013.01);
Abstract
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).